RESUMO
Botulinum toxin is the most poisonous substance known, and is believed to be a highly lethal as a biological weapon; researchers of the toxin are exposed to this hazard. Botulinum toxoid vaccines have been produced and used in Japan. However, since clinical studies involving these vaccines were conducted before establishment of the Ethical Guidelines for Clinical Research in Japan, their immunogenicity and safety were not systematically assessed. In this study, we produced a new tetravalent (type A, B, E, and F) botulinum toxoid vaccine, the first ever to be derived from M toxin, and conducted quality control tests with reference to the Minimum Requirements in Japan for adsorbed tetanus toxoid vaccine. Subsequently, a clinical study using the new vaccine in 48 healthy adult volunteers was conducted according to the guidelines in Japan. No clinically serious adverse event was noted. Neutralizing antibody titers for each type of toxin in the participants' sera, 1 month after the 4th injection were more than 0.25 IU/mL, indicating sufficient protection. This study demonstrated that the vaccine has marked immunogenicity and is safe for use in humans.
Assuntos
Vacinas Bacterianas/imunologia , Toxinas Botulínicas/imunologia , Botulismo/prevenção & controle , Toxoides/imunologia , Adulto , Animais , Antitoxinas/sangue , Vacinas Bacterianas/administração & dosagem , Vacinas Bacterianas/efeitos adversos , Vacinas Bacterianas/isolamento & purificação , Ensaio de Imunoadsorção Enzimática , Feminino , Cobaias , Voluntários Saudáveis , Humanos , Japão , Masculino , Camundongos , Pessoa de Meia-Idade , Toxoides/administração & dosagem , Toxoides/efeitos adversos , Toxoides/isolamento & purificação , Resultado do Tratamento , Adulto JovemRESUMO
We have established a manufacturing system for a Vero cell-derived inactivated Japanese encephalitis vaccine at a 500l scale. The production system involves expansion of Vero cells using microcarrier, followed by virus infection. Except for an additional purification step, the downstream purification processes are similar to those used for the current mouse brain-derived vaccine; cell removal, concentration and removal of low-molecular weight impurities by membrane filtration, formalin-inactivation, sucrose density gradient ultracentrifugation, and Sulfate-Cellulofine column chromatography are conducted. The antigen obtained from the manufacturing system was highly purified and its physico-chemical and immunological properties were comparable with those of antigen derived from mouse brains. Our system is very simple and could be easily scaled-up to allow vaccine production at a several thousand litre scale.
